Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY2R | P49146 | 11/20 | 0.41 |
| ▸ | MTTP | P55157 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.39 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4997581 | 0.82 | PIM2 (0.48) | ALDH1A1MAPTSLC6A9 | |
| SCHEMBL4994725 | 0.81 | GRM5 (0.41) | GRM5MAPTPARP1 | |
| SCHEMBL4996073 | 0.81 | LMNA (0.52) | ALDH1A1MAPT | |
| SCHEMBL4995405 | 0.81 | L3MBTL1 (0.46) | ALDH1A1MAPTSLC6A9 | |
| SCHEMBL4996244 | 0.81 | PIM1 (0.39) | MAPTPARP1 | |
| SCHEMBL4997015 | 0.78 | NPY2R (0.42) | NPY2RALDH1A1MAPT | |
| SCHEMBL4992025 | 0.78 | NPC1 (0.47) | ALDH1A1MAPT | |
| SCHEMBL5000697 | 0.77 | ALDH1A1 (0.46) | ALDH1A1MAPT | |
| SCHEMBL5000640 | 0.76 | RAF1 (0.51) | ALDH1A1MAPT | |
| SCHEMBL5000846 | 0.76 | CYP11B1 (0.47) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | AXXIMA PHARMACEUTICALS AG (DE) | 2008-08-14 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194574-A1 | Pyrazine Derivatives As Effective Compounds Against Infectious Diseases | PRNP, PSEN1, PPP5C | NPY2R 1004/4885MTTP 4471/4885ALDH1A1 1034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.